Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Mars Petcare acquires AniCura
Mandate

Mars Petcare acquires AniCura

June 13, 2018 M&A

Vinge advises Fidelio Capital in connection with entering into an agreement with Mars Petcare regarding Mars Petcare's acquisition of AniCura.

AniCura was founded in 2011 by Fidelio Capital and The Animal Hospital Foundation in Greater Stockholm through the first merger of companion animal hospitals in the Nordic region. Since then the company grown to become one of Europe’s leading providers of high-quality veterinary care for companion animals and today AniCura has more than 4,000 veterinary professionals who provides modern, high-quality veterinary care for pets at 200 European locations across seven European countries. In 2014, Nordic Capital joined the company as a majority owner, with Fidelio Capital remaining as a significant shareholder. The acquisition is subject to customary regulatory approvals.

Vinge’s team consisted of, among others, Jonas Bergström and Joacim Rydergård.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024